Rosenbaum Jay D. boosted its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 4.1% during the second quarter, Holdings Channel reports. The fund owned 5,100 shares of the medical research company’s stock after buying an additional 200 shares during the period. Thermo Fisher Scientific comprises approximately 1.8% of Rosenbaum Jay D.’s portfolio, making the stock its 25th largest position. Rosenbaum Jay D.’s holdings in Thermo Fisher Scientific were worth $890,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Proficio Capital Partners LLC raised its position in shares of Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the last quarter. Cribstone Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after buying an additional 50 shares during the last quarter. Independent Portfolio Consultants Inc. raised its position in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the last quarter. Sharkey Howes & Javer raised its position in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares during the last quarter. Finally, CWM LLC raised its position in shares of Thermo Fisher Scientific by 17.0% in the second quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 103 shares during the last quarter. 87.15% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Inc (NYSE:TMO) traded up 0.87% during trading on Friday, hitting $173.23. The company had a trading volume of 2,202,642 shares. The company has a market capitalization of $67.58 billion, a price-to-earnings ratio of 30.18 and a beta of 1.06. The stock has a 50-day moving average of $176.78 and a 200 day moving average of $165.46. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.03 earnings per share. Equities analysts forecast that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is presently 10.45%.

ILLEGAL ACTIVITY NOTICE: This story was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/13/rosenbaum-jay-d-boosts-stake-in-thermo-fisher-scientific-inc-nysetmo.html.

Several research analysts have weighed in on the company. Bank of America Corporation upped their target price on Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Jefferies Group LLC increased their price objective on Thermo Fisher Scientific from $160.00 to $175.00 and gave the company a “hold” rating in a report on Friday, April 28th. BidaskClub lowered Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, Citigroup Inc. reissued a “buy” rating and set a $201.00 price objective (up previously from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. One equities research analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus price target of $188.56.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the sale, the chief executive officer now directly owns 269,279 shares in the company, valued at $46,528,718.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the sale, the chief financial officer now owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The disclosure for this sale can be found here. Insiders have sold 27,188 shares of company stock valued at $4,702,223 over the last 90 days. Corporate insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.